Cartesian Therapeutics: Investment, Director Appointment, and Trial Success

Cartesian Therapeutics (RNAC) just unveiled an announcement.

Cartesian Therapeutics, Inc. has secured a $130 million private investment through a stock sale, with the transaction set to close on July 3, 2024. This includes selling common and Series B Non-Voting Convertible Preferred shares at $20 each. Additionally, the company appointed Dr. Kemal Malik as a Class II director, who brings a wealth of experience from his previous roles, including at Bayer AG. Dr. Malik will also receive compensation in the form of cash retainers and stock options. Moreover, the company has announced promising results from a Phase 2b trial of Descartes-08, a potential treatment for myasthenia gravis, and will be hosting a conference call to discuss these findings.

Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.